VFEND (voriconazole) by Pfizer is cytochrome p450 3a4 inhibitors [moa]. First approved in 2003.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
VFEND (voriconazole) is a small-molecule antifungal agent approved in 2003 that works by inhibiting cytochrome P450 3A4, disrupting fungal cell membrane synthesis. It is indicated for serious invasive fungal infections, including aspergillosis and candidiasis, in immunocompromised patients. The drug is administered orally as a tablet formulation.
As LOE approaches, the brand team is likely consolidating and focusing on defensive strategies and managed markets rather than expansion.
Cytochrome P450 3A4 Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study on the Drug Interaction Between Buagafuran and Voriconazole
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Worked on VFEND at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VFEND offers experience in managing a mature, established infectious disease product with strong clinical legacy but limited growth runway. Career advancement requires focus on defensive strategies, managed markets, and lifecycle optimization rather than field expansion.